| Summary: | Abstract Background Recently, actinomycetes have attracted the attention of researchers worldwide. They can produce secondary metabolites with antibacterial, antifungal, antiviral, and antitumoral properties. Results Streptomyces sp. MER4 (accession no. KM099241) was isolated from the pyramid region, Giza, Egypt. This strain was previously mentioned for its ability to produce antidermatophytic bioactive metabolites. Scale-up fermentation and fractionation of the extract has been established using different solvents. The ethanol fraction exhibited a considerable antidermatophytic effect (19.8, 21.2, and 20.3 mm for Trichophyton mentagrophyes, Microsporum canis, and Microsporum gypseum, respectively), antimicrobial (10, 8, 7, 9, and 9 mm for Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans, Bacillus subtilis, and Aspergillus niger, respectively), and cytotoxic activity (inhibition of 78.48%). Further purification of the ethanol fraction was done, and one promising compound was produced. This compound was intensely characterized and elucidated by studying its spectral date including nuclear magnetic resonance (NMR) and liquid chromatography mass spectroscopy (LC/MS). The produced compound was identified as JBIR-58 (salicylamide) derivative compound. Conclusions Streptomyces sp. MER4 has been identified genetically and screened for its ability to produce bioactive compound with antibacterial antitumor and antidermatophytic agent. The scale-up fermentation, purification, and structure elucidation led to pure compound named salicylamide derivatives JBIR-58 from the fermentation broth of Streptomyces sp. MER4.
|
|---|
